Valdiviezo Lama News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Osimertinib plus chemotherapy confers superior post-progression survival outcomes vs osimertinib alone in patients with EGFR-mutated NSCLC.

Natalia isabel valdiviezo lamaValdiviezo lamaWorld health organizationNational institute of neoplastic diseasesEuropean lung cancer congressLung cancer congressNational instituteNeoplastic diseasesChinese asianOsimertinib plus chemotherapyPatients with egfr mutated nsclc